Ceftaroline meets Phase III endpoint

Forest Laboratories Inc. (NYSE:FRX) said top-line pooled data from the Phase III FOCUS I and FOCUS II trials showed that ceftaroline met the primary endpoint of non-inferiority to Rocephin ceftriaxone on clinical cure rate in the clinically evaluable population (84.3% vs. 77.7%). The trials enrolled 1,241 hospitalized adults with moderate to severe community-acquired pneumonia (CAP) caused by bacteria who required treatment with IV antibiotics. ...